clinical outcomes, ingredient by ingredient.
shown
Every active in the Encap system, traced to published evidence. No marketing claims — just the measured outcome and the citation behind it.
three steps to 3× deeper.
Each active is wrapped in a sub-micron, lipid-compatible shell — shielded from air, light and pH, so it arrives chemically intact instead of oxidising in the bottle.
The shell is engineered to cross the stratum corneum — the lipid layer that repels water-soluble actives and leaves conventional serums sitting on the surface.
Actives reach the layer where they act — fibroblasts for collagen, the follicle wall for clarity — released slowly rather than in a single irritating burst.
Reduction in total wrinkle surface area, with a 9.1% drop in wrinkle length, in just 14 days.
Improvement in microrelief structure and a 15% increase in epidermal thickness in post-menopausal skin.
Clinically equivalent to 0.5% retinol for wrinkle surface area and hyperpigmentation — with significantly higher tolerability.
Dose-dependent attenuation of oxidative stress (ROS) and stimulation of Type I collagen synthesis.
Mean reduction in acne severity scores (IGA) over 60 days, with zero adverse events recorded.
49.26% decrease in transepidermal water loss and a 23.65% reduction in surface sebum in 21 days.
200% increase in skin moisture and a 40% reduction in TEWL within 7 days via the Ectoin Hydrocomplex.
Comparable in clinical efficacy to 1.0% clindamycin for inflammatory acne — without antibiotic resistance.
marketing claims, removed.
Every figure is tied to a specific active at the concentration we use — never a finished-product halo claim.
Outcomes are drawn from published, peer-referenced studies — linked to the source wherever available.
Wrinkle area, TEWL, sebum, ATP — quantified endpoints, not adjectives or before-and-after lighting.
Ingredient- and population-level data informs expectations. It is not a guarantee of an individual outcome.